Semax

Clinical References

1. Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006;1117(1):54-60. PubMed 16996037
2. Asmarin IP, Nezavibat'ko VN, Miasoedov NF, et al. A nootropic adrenocorticotropin analog 4-10-semax (15 years experience in its design and study). Zh Vyssh Nerv Deiat Im I P Pavlova. 1997;47(2):420-430. PubMed 9173745
3. Shadrina M, Kolomin T, Agapova T, et al. Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action. J Mol Neurosci. 2010;41(1):30-35. PubMed 19662538
4. Eremin KO, Kudrin VS, Saransaari P, et al. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochem Res. 2005;30(12):1493-1500. PubMed 16362768
5. Grivennikov IA, Dolotov OV, Zolotarev YA, et al. Effects of behaviorally active ACTH (4-10) analogue - Semax on rat basal forebrain cholinergic neurons. Restor Neurol Neurosci. 2008;26(1):35-43. PubMed 18431004
6. Safarova ER, Shram SI, Zolotarev YA, et al. Effect of Semax peptide on survival of cultured rat pheochromocytoma cells during oxidative stress. Bull Exp Biol Med. 2003;135(3):268-271. PubMed 12802399
7. Storozhevykh TP, Tukhbatova GR, Senilova YE, et al. Effects of semax and its Pro-Gly-Pro fragment on calcium homeostasis of neurons and their survival under conditions of glutamate toxicity. Bull Exp Biol Med. 2007;143(5):601-604. PubMed 18239779
8. Dergunova LV, Dmitrieva VG, Filippenkov IB, et al. The peptide drug ACTH(4-7)PGP (Semax) suppresses mRNA transcripts encoding proinflammatory mediators induced by reversible ischemia of the rat brain. Mol Biol (Mosk). 2021;55(3):402-411. PubMed 34097675
9. Gusev EI, Martynov MY, Kostenko EV, et al. The efficacy of semax in the tretament of patients at different stages of ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(3 Vyp 2):61-68. PubMed 29798983
10. Shevchenko KV, Nagaev IIu, Alfeeva LIu, et al. Kinetics of Semax penetration into the brain and blood of rats after its intranasal administration. Bioorg Khim. 2006;32(1):64-70. PubMed 16523722
11. Polunin GS, Nurieva SM, Baiandin DL, et al. Evaluation of therapeutic effect of new Russian drug semax in optic nerve disease. Vestn Oftalmol. 2000;116(1):15-18. PubMed 10741256
12. Gusev EI, Skvortsova VI, Chukanova EI. Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency. Zh Nevrol Psikhiatr Im S S Korsakova. 2005;105(2):35-40. PubMed 15792140

Dosage

200mcg – 600mcg daily (intranasal)

Cycle

2–4 weeks

Form

10mg lyophilised powder

Purity

≥98%

Molecular formula

C₃₇H₅₁N₉O₁₀S

Storage

2–8°C refrigerated

Certificate of Analysis

View COA

1. 1

   Reconstitute for Nasal Use

   Add 2ml of BAC water to the 10mg vial, producing a concentration of 5mg/ml (5,000mcg/ml). Transfer the solution to a nasal spray bottle. A standard nasal sprayer typically delivers 0.1ml per actuation. At this concentration, each spray provides approximately 500mcg.

2. 2

   Dosing Protocol

   When discussing Semax dosage, a common range is 200–600 mcg daily, administered intranasally in the morning or early afternoon.
   Dosage usually starts at 200 mcg and is titrated according to personal experience. Administration can be split into morning and early afternoon. Use in the evening is not advised due to the fact that increased alertness has been reported by some individuals.

3. 3

   Cycle

   The regular cycle takes 2–4 weeks, followed by a two-week break. Studies have been carried out on the effects of Semax on BDNF production after the end of administration. Cycling is a standard method for those using this peptide in the long term.

Free shipping on orders over £220.

• Shipping
• Refund Policy